Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Sells $62,730.16 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYCGet Free Report) CEO Kevin Lee sold 3,194 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $19.64, for a total value of $62,730.16. Following the transaction, the chief executive officer now directly owns 384,076 shares in the company, valued at $7,543,252.64. The sale was disclosed in a document filed with the SEC, which is available at this link.

Bicycle Therapeutics Trading Up 0.1 %

Shares of NASDAQ:BCYC traded up $0.02 during trading on Monday, reaching $20.23. 131,895 shares of the company traded hands, compared to its average volume of 351,226. The company has a current ratio of 10.42, a quick ratio of 10.42 and a debt-to-equity ratio of 0.09. Bicycle Therapeutics plc has a 52-week low of $12.54 and a 52-week high of $27.50. The business’s fifty day moving average is $22.19 and its 200-day moving average is $21.66. The firm has a market capitalization of $865.44 million, a price-to-earnings ratio of -4.61 and a beta of 0.93.

Bicycle Therapeutics (NASDAQ:BCYCGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.63. The business had revenue of $19.53 million for the quarter, compared to analyst estimates of $6.06 million. Bicycle Therapeutics had a negative net margin of 404.14% and a negative return on equity of 49.35%. The company’s revenue for the quarter was up 298.9% on a year-over-year basis. As a group, analysts forecast that Bicycle Therapeutics plc will post -4.44 EPS for the current year.

Hedge Funds Weigh In On Bicycle Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Polar Capital Holdings Plc increased its stake in shares of Bicycle Therapeutics by 33.2% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,011,500 shares of the company’s stock worth $20,321,000 after acquiring an additional 252,000 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Bicycle Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company’s stock worth $122,000 after acquiring an additional 1,706 shares during the last quarter. Woodstock Corp increased its holdings in shares of Bicycle Therapeutics by 4.5% during the fourth quarter. Woodstock Corp now owns 21,479 shares of the company’s stock valued at $388,000 after acquiring an additional 926 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Bicycle Therapeutics by 489.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,001 shares of the company’s stock worth $72,000 after purchasing an additional 3,322 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its stake in Bicycle Therapeutics by 3.9% in the 4th quarter. Handelsbanken Fonder AB now owns 139,800 shares of the company’s stock worth $2,528,000 after purchasing an additional 5,300 shares in the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on BCYC shares. Needham & Company LLC reiterated a “buy” rating and set a $43.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, April 10th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of Bicycle Therapeutics in a report on Friday, May 3rd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $46.86.

Read Our Latest Stock Report on BCYC

Bicycle Therapeutics Company Profile

(Get Free Report)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

See Also

Insider Buying and Selling by Quarter for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.